Apr 17 |
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
|
Apr 3 |
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
|
Apr 3 |
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript
|
Apr 2 |
Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript
|
Apr 2 |
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
|
Mar 31 |
Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
|
Mar 27 |
Evaxion Biotech ADS GAAP EPS of -$0.81
|
Mar 27 |
Evaxion Announces Business Update and Full Year 2023 Financial Results
|
Mar 22 |
When Will Evaxion Biotech A/S (NASDAQ:EVAX) Turn A Profit?
|
Mar 19 |
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
|